What is ANI Pharmaceuticals's other commercial liabilities?

ANI Pharmaceuticals (ANIP) reported other commercial liabilities of $13.74M in Q1 2026.

How has ANI Pharmaceuticals's other commercial liabilities changed year-over-year?

ANI Pharmaceuticals's other commercial liabilities increased by 14.2% year-over-year, from $12.03M to $13.74M.

What is the long-term trend for ANI Pharmaceuticals's other commercial liabilities?

Over 5 years (2020 to 2025), ANI Pharmaceuticals's other commercial liabilities has grown at a 47.2% compound annual growth rate (CAGR), from $2.46M to $16.97M.

ANI Pharmaceuticals ANIP Other Commercial Liabilities

Other Commercial Liabilities at other companies

AnaptysBio, Inc.ANAB

——

ALN

Alnylam PharmaceuticalsALNY

——

Aurinia PharmaceuticalsAUPH

——

AmgenAMGN

——

Viridian Therapeutics, Inc.VRDN

——

Ultragenyx PharmaceuticalRARE

——

Other financials

Income statement

See full

Revenue$237.5M+20.5%

Gross profit$143.9M+16.0%

Operating income$38.9M+48.5%

Net income$29.5M+88.1%

EPS (diluted)$1.28+85.5%

Balance sheet

See full

Cash & equivalents$311.2M+108%

Total debt$305.3M-3.5%

Total equity$562.3M+34.3%

Total assets$1.4B+10.0%

Cash flow

See full

Operating cash flow$58.4M+66.8%

CapEx$6.1M+146%

Free cash flow$52.3M+60.8%

Valuation

See full

Market cap$1.89B+18.3%

Enterprise value$1.88B+5.8%

P/E20.5×—

P/S2×-0.3×

Profitability

See full

Gross margin60.8%+1.5pp

Operating margin13.4%—

Net margin10%+8.1pp

FCF margin20.7%+10.8pp

Returns & leverage

See full

Return on equity18.8%+15.6pp

Debt / equity0.5×-0.2×

Current ratio3.1×+0.5×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about ANI Pharmaceuticals's other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ANI Pharmaceuticals's other commercial liabilities?: ANI Pharmaceuticals (ANIP) reported other commercial liabilities of $13.74M in Q1 2026.
How has ANI Pharmaceuticals's other commercial liabilities changed year-over-year?: ANI Pharmaceuticals's other commercial liabilities increased by 14.2% year-over-year, from $12.03M to $13.74M.
What is the long-term trend for ANI Pharmaceuticals's other commercial liabilities?: Over 5 years (2020 to 2025), ANI Pharmaceuticals's other commercial liabilities has grown at a 47.2% compound annual growth rate (CAGR), from $2.46M to $16.97M.